Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.

Amphotericin B Antifungal Agents / therapeutic use Azoles / pharmacology COVID-19 / complications Coinfection / drug therapy Humans Nitriles Pulmonary Aspergillosis / complications Pyridines SARS-CoV-2 Triazoles Voriconazole / therapeutic use

Journal

The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150

Informations de publication

Date de publication:
06 2021
Historique:
received: 11 09 2020
revised: 10 10 2020
accepted: 14 10 2020
pubmed: 18 12 2020
medline: 2 7 2021
entrez: 17 12 2020
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.

Identifiants

DOI: 10.1016/S1473-3099(20)30847-1 PMID: 33333012 PMC: PMC7833078
pubmed: 33333012
pii: S1473-3099(20)30847-1
doi: 10.1016/S1473-3099(20)30847-1
pmc: PMC7833078
pii:
doi:

Substances chimiques

Antifungal Agents 0
Azoles 0
Nitriles 0
Pyridines 0
Triazoles 0
liposomal amphotericin B 0
isavuconazole 60UTO373KE
Amphotericin B 7XU7A7DROE
Voriconazole JFU09I87TR

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e149-e162

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

N Engl J Med. 2002 Aug 8;347(6):408-15
pubmed: 12167683
Clin Infect Dis. 2016 Aug 15;63(4):e1-e60
pubmed: 27365388
Ann Intern Med. 2015 Jan 20;162(2):81-9
pubmed: 25599346
Science. 2019 Oct 25;366(6464):407
pubmed: 31649174
Ann Intensive Care. 2015 Dec;5(1):44
pubmed: 26603290
Expert Rev Anti Infect Ther. 2015 Jun;13(6):799-815
pubmed: 25947367
Mycoses. 2021 Jan;64(1):55-59
pubmed: 32918497
Epidemiol Infect. 2012 Oct;140(10):1848-52
pubmed: 22152763
J Fungi (Basel). 2020 Jun 24;6(2):
pubmed: 32599813
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Am J Respir Crit Care Med. 2012 Jul 1;186(1):56-64
pubmed: 22517788
Mycoses. 2020 Aug;63(8):766-770
pubmed: 32585069
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Am J Med. 1989 Jun;86(6 Pt 2):791-800
pubmed: 2543220
Lancet Respir Med. 2020 Jun;8(6):e48-e49
pubmed: 32445626
J Fungi (Basel). 2020 Jul 10;6(3):
pubmed: 32664423
Antimicrob Agents Chemother. 2013 Jul;57(7):3262-7
pubmed: 23629724
Ann Intensive Care. 2020 Jun 1;10(1):71
pubmed: 32488446
Lancet Microbe. 2020 Jun;1(2):e53-e55
pubmed: 32835328
Open Forum Infect Dis. 2020 Mar 23;7(4):ofaa105
pubmed: 32284951
Clin Infect Dis. 2021 Dec 6;73(11):e3606-e3614
pubmed: 32719848
Travel Med Infect Dis. 2020 Nov - Dec;38:101752
pubmed: 32470620
Chest. 2020 Sep;158(3):1268-1281
pubmed: 32361152
Clin Microbiol Infect. 2019 Jul;25(7):799-806
pubmed: 30580035
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Med Mycol. 2019 Apr 1;57(Supplement_2):S168-S178
pubmed: 30816967
Am J Respir Crit Care Med. 2020 Jul 1;202(1):132-135
pubmed: 32396381
Eur Respir J. 2016 Mar;47(3):954-66
pubmed: 26743480
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666
pubmed: 32442256
Clin Infect Dis. 2007 Jan 1;44(1):2-12
pubmed: 17143808
Med Mycol Case Rep. 2021 Mar;31:11-14
pubmed: 32837879
Med Mycol. 2009;47 Suppl 1:S271-81
pubmed: 18654923
Mycoses. 2019 Aug;62(8):651-658
pubmed: 31066092
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Med Microbiol. 2015 Jul;64(7):702-707
pubmed: 26002943
Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38
pubmed: 29544767
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Mycoses. 2020 Jun;63(6):528-534
pubmed: 32339350
Am J Respir Crit Care Med. 2020 Jul 15;202(2):284-287
pubmed: 32412787
Eur J Med Res. 2011 Apr 28;16(4):159-66
pubmed: 21486730
J Bronchology Interv Pulmonol. 2020 Oct;27(4):e52-e54
pubmed: 32195687
J Fungi (Basel). 2020 Jun 22;6(2):
pubmed: 32580296
Mycoses. 2018 Mar;61(3):201-205
pubmed: 29112326
Ann Intern Med. 2020 May 5;172(9):629-632
pubmed: 32163542
Am J Respir Crit Care Med. 2020 Oct 15;202(8):1171-1173
pubmed: 32668167
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Lancet. 2020 Jul 25;396(10246):e6-e7
pubmed: 32653078
Mycoses. 2016 Aug;59(8):480-93
pubmed: 27324802
J Antimicrob Chemother. 2017 Dec 01;72(12):3406-3413
pubmed: 28961714
Clin Infect Dis. 2021 Jul 15;73(2):e445-e454
pubmed: 32651997
Lancet Microbe. 2020 Jul;1(3):e107
pubmed: 32835341
Clin Microbiol Infect. 2019 Dec;25(12):1501-1509
pubmed: 31102782
Clin Infect Dis. 2021 Oct 5;73(7):e1634-e1644
pubmed: 32860682
Clin Vaccine Immunol. 2008 Jul;15(7):1095-105
pubmed: 18463222
J Fungi (Basel). 2020 Jun 06;6(2):
pubmed: 32517166
Drug Des Devel Ther. 2018 Apr 30;12:1033-1044
pubmed: 29750016
J Infect. 2019 Jun;78(6):484-490
pubmed: 30974130
J Crit Care. 2017 Aug;40:119-127
pubmed: 28384600
Intensive Care Med. 2020 Aug;46(8):1524-1535
pubmed: 32572532
Eur J Clin Microbiol Infect Dis. 2010 Nov;29(11):1387-94
pubmed: 20703506
Lancet Respir Med. 2018 Oct;6(10):782-792
pubmed: 30076119
Cochrane Database Syst Rev. 2019 Sep 03;9:CD009551
pubmed: 31478559
J Thorac Imaging. 2020 Nov 1;35(6):346-353
pubmed: 32558725
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30670426
Med Mycol. 2020 Jun 1;58(4):444-452
pubmed: 31290552
Clin Microbiol Infect. 2019 Dec;25(12):1563.e1-1563.e3
pubmed: 31445208
Med Mycol. 2020 Jul 1;58(5):579-592
pubmed: 31342066
Clin Infect Dis. 2007 May 15;44(10):1289-97
pubmed: 17443465
Clin Infect Dis. 2015 Oct 15;61(8):1293-303
pubmed: 26113653
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
Antimicrob Agents Chemother. 2018 Jul 27;62(8):
pubmed: 29891595
Mycoses. 2018 Apr;61(4):256-260
pubmed: 29178247
Clin Infect Dis. 2021 May 4;72(9):1577-1584
pubmed: 32188971
Mycoses. 2020 Feb;63(2):122-130
pubmed: 31660650
Clin Infect Dis. 2018 Nov 13;67(11):1705-1711
pubmed: 29684106
J Antimicrob Chemother. 2016 Mar;71(3):718-26
pubmed: 26612870
Eur Respir J. 2015 May;45(5):1463-78
pubmed: 25792631
Med Mycol Case Rep. 2021 Mar;31:15-18
pubmed: 32837880
BMJ Case Rep. 2020 May 12;13(5):
pubmed: 32404321
Lancet. 2016 Feb 20;387(10020):760-9
pubmed: 26684607
Am J Respir Crit Care Med. 2008 Jan 1;177(1):27-34
pubmed: 17885264
Clin Infect Dis. 2021 Oct 5;73(7):e1737-e1744
pubmed: 32866234

Auteurs

Philipp Koehler (P)

Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Department I of Internal Medicine, European Excellence Center for Medical Mycology (ECMM), University Hospital Cologne, Cologne, Germany.

Matteo Bassetti (M)

Infectious Diseases Clinic, Department of Health Sciences, University of Genoa, Genoa, Italy; Policlinico San Martino Hospital, Genoa, Italy.

Arunaloke Chakrabarti (A)

Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Sharon C A Chen (SCA)

Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Sydney, NSW, Australia; Department of Infectious Diseases, Westmead Hospital, Sydney, NSW, Australia; School of Medicine, University of Sydney, Sydney, NSW, Australia.

Arnaldo Lopes Colombo (AL)

Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.

Martin Hoenigl (M)

Clinical and Translational Fungal-Working Group and Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA; Section of Infectious Diseases and Tropical Medicine and Division of Pulmonology, Medical University of Graz, Graz, Austria.

Nikolay Klimko (N)

Department of Clinical Mycology, Allergology and Immunology, North Western State Medical University, St Petersburg, Russia.

Cornelia Lass-Flörl (C)

Institute of Hygiene and Medical Microbiology, ECMM, Medical University of Innsbruck, Innsbruck, Austria.

Rita O Oladele (RO)

Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos, Lagos, Nigeria.

Donald C Vinh (DC)

Division of Infectious Diseases, Department of Medicine, Department of Medical Microbiology, and Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, McGill University Health Centre, Montreal, QC, Canada.

Li-Ping Zhu (LP)

Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.

Boris Böll (B)

Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, European Excellence Center for Medical Mycology (ECMM), University Hospital Cologne, Cologne, Germany.

Roger Brüggemann (R)

Department of Pharmacy, ECMM, Center of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Center, Radboud University, Nijmegen, Netherlands; Radboudumc Institute of Health Science, ECMM, Center of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Center, Radboud University, Nijmegen, Netherlands.

Jean-Pierre Gangneux (JP)

Université de Rennes, CHU de Rennes, EHESP, Institut de Recherche en Santé, Environnement et travail, Inserm UMR_S 1085, Rennes, France.

John R Perfect (JR)

Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Duke University, Durham, NC, USA.

Thomas F Patterson (TF)

University of Texas Health San Antonio, San Antonio, TX, USA; University Health, San Antonio, TX, USA; South Texas Veterans Health Care System, San Antonio, TX, USA.

Thorsten Persigehl (T)

Faculty of Medicine, University of Cologne, Cologne, Germany; Department of Radiology, University Hospital Cologne, Cologne, Germany.

Jacques F Meis (JF)

Department of Medical Microbiology, ECMM, Center of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Center, Radboud University, Nijmegen, Netherlands; Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, Netherlands; Bioprocess Engineering and Biotechnology Graduate Program, Federal University of Paraná, Curitiba, Brazil.

Luis Ostrosky-Zeichner (L)

Division of Infectious Diseases, McGovern Medical School, University of Texas, Houston, TX, USA.

P Lewis White (PL)

Mycology Reference Laboratory, Public Health Wales Microbiology Cardiff, Cardiff, UK.

Paul E Verweij (PE)

Department of Medical Microbiology, ECMM, Center of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Center, Radboud University, Nijmegen, Netherlands; Center for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, National Institute for Public Health and the Environment, Bilthoven, Netherlands.

Oliver A Cornely (OA)

Faculty of Medicine, University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Department I of Internal Medicine, European Excellence Center for Medical Mycology (ECMM), University Hospital Cologne, Cologne, Germany; Clinical Trials Centre Cologne, ZKS Köln, Cologne, Germany; German Center for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany. Electronic address: oliver.cornely@uk-koeln.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Lactones › Amphotéricine B › Defining and managing COVID-19-associated...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antifongiques › Defining and managing COVID-19-associated...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Defining and managing COVID-19-associated...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Defining and managing COVID-19-associated...
questionsmedicales.fr › Infection › Co-infection › Defining and managing COVID-19-associated...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Defining and managing COVID-19-associated...
questionsmedicales.fr › Composés chimiques organiques › Nitriles › Defining and managing COVID-19-associated...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Maladies pulmonaires › Aspergillose pulmonaire › Defining and managing COVID-19-associated...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Defining and managing COVID-19-associated...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Defining and managing COVID-19-associated...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Triazoles › Defining and managing COVID-19-associated...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Triazoles › Voriconazole › Defining and managing COVID-19-associated...